search

Active clinical trials for "Anemia, Hemolytic"

Results 41-50 of 88

Sirolimus for Autoimmune Disease of Blood Cells

Autoimmune PancytopeniaAutoimmune Lymphoproliferative Syndrome (ALPS)10 more

Treatment for patients with autoimmune destruction of blood cells is poor. The part of the body that fights infections is called the immune system and white blood cells (WBCs) are part of the immune system. Normally, a person's body creates WBCs to fight infections and eliminates WBCs which have stopped helping the body function. Patients with autoimmune destruction of blood cells have difficulty eliminating old WBCs. The abnormal WBCs build up and can damage other healthy cells, which can lead to anemia, fatigue, jaundice, internal bleeding, infection, and cancer. Few effective medications exist for treatment for patients with autoimmune cytopenias and those commonly used are fraught with side effects. Nevertheless, as scientific understanding of autoimmune diseases has improved, more directed and less toxic therapies are becoming available. A number of groups have been studying the efficacy of a medication called sirolimus in patients with autoimmune diseases. This medicine has been FDA-approved for over 20 years. Sirolimus is a medicine used in children with other diseases. Sirolimus works, in part, by eliminating old and abnormal WBCs. Our group and others have shown that sirolimus is effective in mice with autoimmunity and in children with a rare condition called Autoimmune Lymphoproliferative Syndrome (ALPS). We believe sirolimus will help children with autoimmune cytopenias. We believe it will improve their symptoms and make them less sick. We propose to study sirolimus in children with chronic and/or refractory autoimmune cytopenias.

Completed16 enrollment criteria

A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants...

Pyruvate Kinase DeficiencyAnemia1 more

Study AG348-C-006 evaluated the efficacy and safety of orally administered AG-348 as compared with placebo in participants with pyruvate kinase (PK) deficiency, who were not regularly receiving blood transfusions. Participants were randomized 1:1 to receive either AG-348 or a matching placebo.

Completed24 enrollment criteria

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium...

Warm Antibody Autoimmune Hemolytic Anemia

The primary objective of this study is to assess the efficacy of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).

Completed11 enrollment criteria

Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease

Cold Agglutinin DiseaseAutoimmune Hemolytic Anemia

Prospective, non-randomized multicenter study on the safety and efficacy of combination therapy with bendamustine and rituximab for chronic cold agglutinin disease.

Completed19 enrollment criteria

A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin Disease

Autoimmune Haemolytic Anaemia

Primary Objective: To assess the safety and tolerability in participants with cold agglutinin disease (CAD), after a single dose of intravenous (IV) BIVV020 Secondary Objectives: To assess, in participants with cold agglutinin disease, after a single dose of intravenous (IV) BIVV020: The effect of BIVV020 on complement mediated hemolysis The pharmacodynamics (PD) of BIVV020 relating to complement inhibition The pharmacokinetics (PK) of BIVV020 The immunogenicity of BIVV020

Completed18 enrollment criteria

Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL)...

Chronic Lymphocytic Leukemia

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving more than one drug (combination chemotherapy) together with rituximab may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving combination chemotherapy together with rituximab works in treating patients with chronic lymphocytic leukemia (CLL) that has not responded to fludarabine (closed to entry as of 10/2006), CLL with autoimmune hemolytic anemia, or Richter transformation.

Completed13 enrollment criteria

Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

Sickle Cell DiseaseIron Overload1 more

This study will examine the long-term safety and efficacy of Deferasirox in patients with sickle cell disease and iron overload from repeated blood transfusions.

Completed29 enrollment criteria

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm...

Warm Autoimmune Hemolytic Anemia (wAIHA)

This study will evaluate the safety and tolerability of ANX005 in participants with Warm Autoimmune Hemolytic Anemia (wAIHA).

Completed19 enrollment criteria

The Significance of Release of T-follicular Helper and T-follicular Regulatory Cells in Autoimmune...

Autoimmune Hemolytic Anemia

we study the circulating T-follicular regulatory and T-follicular regulatory cells in autoimmune hemolytic anemia.

Not yet recruiting5 enrollment criteria

Rituximab in Auto-Immune Hemolytic Anemia

Warm Autoimmune Hemolytic Anemia

The hypothesis based on retrospective data is that, the rate of overall response-rate (PR + CR) at 1 year will be much higher in the rituximab arm (80%) than in the placebo arm (20%).Thirty four patients (17 in each arm) will be include (amendment n°6 - 15/10/2013) over a 3 year period (amendment n°3 - 11/12/2012).

Completed25 enrollment criteria
1...456...9

Need Help? Contact our team!


We'll reach out to this number within 24 hrs